MA47420A - Composés inhibiteurs d'oga - Google Patents

Composés inhibiteurs d'oga

Info

Publication number
MA47420A
MA47420A MA047420A MA47420A MA47420A MA 47420 A MA47420 A MA 47420A MA 047420 A MA047420 A MA 047420A MA 47420 A MA47420 A MA 47420A MA 47420 A MA47420 A MA 47420A
Authority
MA
Morocco
Prior art keywords
inhibitor compounds
oga inhibitor
oga
compounds
inhibitor
Prior art date
Application number
MA047420A
Other languages
English (en)
Inventor
José Manuel Bartolomé-Nebreda
Viturro Carlos Manuel Martinez
Andrés Avelino Trabanco-Suárez
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA47420A publication Critical patent/MA47420A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA047420A 2017-02-06 2018-02-06 Composés inhibiteurs d'oga MA47420A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17154751 2017-02-06

Publications (1)

Publication Number Publication Date
MA47420A true MA47420A (fr) 2019-12-11

Family

ID=57965815

Family Applications (1)

Application Number Title Priority Date Filing Date
MA047420A MA47420A (fr) 2017-02-06 2018-02-06 Composés inhibiteurs d'oga

Country Status (8)

Country Link
US (1) US20200048267A1 (fr)
EP (1) EP3577121A1 (fr)
JP (1) JP2020506940A (fr)
CN (1) CN110267961A (fr)
AU (1) AU2018216040A1 (fr)
CA (1) CA3045816A1 (fr)
MA (1) MA47420A (fr)
WO (1) WO2018141984A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017003658B1 (pt) 2014-08-28 2022-12-06 Asceneuron Sa Composto, mistura, método para inibição de uma glicosidase, e, composição farmacêutica
EP3419976B1 (fr) 2016-02-25 2021-04-07 Asceneuron SA Sels d'addition d'acide de dérivés de pipérazine
US11612599B2 (en) 2016-02-25 2023-03-28 Asceneuron Sa Glycosidase inhibitors
AU2017222964B2 (en) 2016-02-25 2020-01-02 Asceneuron S. A. Glycosidase inhibitors
EP3585783A2 (fr) 2016-02-25 2020-01-01 Asceneuron SA Inhibiteurs de la sulfoximine glycosidase
EP3585790A1 (fr) * 2017-02-27 2020-01-01 Janssen Pharmaceutica NV Dérivés de [1,2,4]-triazolo [1,5-a]-pyrimidinyle substitués par de la pipéridine, de la morpholine ou de la pipérazine utilisés en tant qu'inhibiteurs d'oga
EP3672959A1 (fr) 2017-08-24 2020-07-01 Asceneuron SA Inhibiteurs linéaires de la glycosidase
WO2020039028A1 (fr) 2018-08-22 2020-02-27 Asceneuron S. A. Inhibiteurs de tétrahydro-benzoazépine glycosidase
EP3841093B1 (fr) 2018-08-22 2023-06-21 Asceneuron SA Sels d'addition d'acide de succinate et de fumarate de dérivés de pipérazine en tant qu'inhibiteurs de glycosidase
US12016852B2 (en) 2018-08-22 2024-06-25 Asceneuron Sa Pyrrolidine glycosidase inhibitors
US11731972B2 (en) 2018-08-22 2023-08-22 Asceneuron Sa Spiro compounds as glycosidase inhibitors
US12565504B2 (en) 2019-10-29 2026-03-03 Biogen Ma Inc. Spirocyclic O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
WO2025247394A1 (fr) * 2024-05-31 2025-12-04 纽欧申医药(上海)有限公司 Composé hétérocyclique contenant de l'azote, composition pharmaceutique de celui-ci et utilisation associée
WO2026021588A1 (fr) * 2024-07-26 2026-01-29 浙江同源康医药股份有限公司 Inhibiteur d'oga et son utilisation
CN119569746B (zh) * 2025-02-06 2025-05-13 纽欧申医药(上海)有限公司 含氮杂环化合物、其药物组合物及应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA009789B1 (ru) 2002-07-05 2008-04-28 Таргасепт, Инк. N-арилдиазаспирациклические соединения и способы их получения и применения
JPWO2009154132A1 (ja) * 2008-06-19 2011-12-01 Ｍｓｄ株式会社 スピロジアミン−ジアリールケトオキシム誘導体
TW201030007A (en) 2009-02-06 2010-08-16 Gruenenthal Gmbh Substituted spiro-amides as b1r modulators
US20120010186A1 (en) * 2009-03-23 2012-01-12 Merck Frosst Canada Ltd. Heterocyclic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
US9221809B2 (en) * 2011-10-31 2015-12-29 Merck Sharp & Dohme Corp. Aminopyrimidinones as interleukin receptor-associated kinase inhibitors
JP6233855B2 (ja) * 2012-08-08 2017-11-22 ノバルティス・ティーアゲズントハイト・アクチェンゲゼルシャフトＮｏｖａｒｔｉｓ Ｔｉｅｒｇｅｓｕｎｄｈｅｉｔ Ａｇ 殺虫剤としての置換されたアジン類
WO2016015604A1 (fr) * 2014-07-26 2016-02-04 Sunshine Lake Pharma Co., Ltd. Composés en tant que petites molécules inhibitrices de la cdk et leurs utilisations
BR112017003658B1 (pt) * 2014-08-28 2022-12-06 Asceneuron Sa Composto, mistura, método para inibição de uma glicosidase, e, composição farmacêutica
EP4074378A1 (fr) * 2015-07-02 2022-10-19 Janssen Sciences Ireland Unlimited Company Composés antibactériens
WO2017087858A1 (fr) * 2015-11-20 2017-05-26 Abide Therapeutics, Inc. Composés de pyrazole, procédés de production et utilisation
WO2017087863A1 (fr) * 2015-11-20 2017-05-26 Abide Therapeutics, Inc. Composés de pyrazole, procédés de production et utilisation
WO2018026371A1 (fr) * 2016-08-04 2018-02-08 Sunovion Pharmaceuticals Inc. Inhibiteurs doubles de nav1.2/5ht2a pour traiter des troubles du snc

Also Published As

Publication number Publication date
CA3045816A1 (fr) 2018-08-09
CN110267961A (zh) 2019-09-20
EP3577121A1 (fr) 2019-12-11
US20200048267A1 (en) 2020-02-13
WO2018141984A1 (fr) 2018-08-09
AU2018216040A1 (en) 2019-06-20
JP2020506940A (ja) 2020-03-05

Similar Documents

Publication Publication Date Title
MA52939A (fr) Composés inhibiteurs d'oga
MA47575A (fr) Composés inhibiteurs d'oga monocyclique
MA52942A (fr) Composés inhibiteurs d'oga
MA47576A (fr) Composés inhibiteurs d'oga bicyclique
EP3720430A4 (fr) Composés benzocarbonyle
EP3836923A4 (fr) Composés pyrrolo-dipyridine
MA52948A (fr) Composés
EP3691623A4 (fr) Composés de benzosulfonyle
EP3464275A4 (fr) Composés inhibiteurs de l'egfr
MA51669A (fr) Composés
EP3740487A4 (fr) Composés benzamide
DK3497103T3 (da) Pyridopyrimdinon-cdk2/4/6-inhibitorer
MA44725A (fr) Formulations d'un inhibiteur de lsd1
MA53003A (fr) Composés
MA52004A (fr) Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase
EP3562487A4 (fr) Composés inhibiteurs des métalloenzymes
MA49006A (fr) Inhibiteurs d'ip6k
EP3728289A4 (fr) Composés optimisés
EP3464336A4 (fr) Composés
MA52946A (fr) Composés
LT3867247T (lt) Naujieji junginiai
EP3808747A4 (fr) Composé d'imidazopyridinone
MA53648A (fr) Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glucopyranosidase
IL269695A (en) Compounds useful as inhibitors of alcat 1
LT3668879T (lt) Nauji junginiai